Predictive performances of lipid accumulation product vs. adiposity measures for cardiovascular diseases and all-cause mortality, 8.6-year follow-up: Tehran lipid and glucose study

Table 3 Contribution of LAP to the risk of CVD, independent of common CVD risk factors among men and women.

	Men		Women
	HR* (95% CIs)	P-value	HR* (95% CIs)	P-value
Age (years)	1.05 (1.04-1.06)	<0.001	1.06 (1.04-1.08)	<0.001
Smoking	1.86 (1.37-2.51)	<0.001	2.97 (1.36-6.47)	0.006
Premature history of CVD	1.47 (0.94-2.32)	0.094	1.60 (1.01-2.52)	0.044
Diabetes	1.30 (0.81-2.08)	0.271	1.95 (1.13-3.35)	0.017
Antihypertensive drug use	1.42 (0.97-2.08)	0.068	2.04 (1.40-2.98)	<0.001
Systolic blood pressure (mmHg)	1.40 (1.24-1.58)	0.000	1.23 (1.04-1.46)	0.014
Intervention	0.76 (0.57-1.01)	0.059	0.96 (0.67-1.38)	0.842
Non-HDL-C (mmol.l^-1)	1.34 (1.15-1.56)	<0.001	1.25 (1.05-1.50)	0.014
HDL-C (mmol.l^-1)	0.81 (0.67-0.97)	0.022	1.06 (0.88-1.28)	0.547
FPG (mmol.l^-1)	1.29 (0.97-1.71)	0.075	0.81 (0.60-1.09)	0.169
2h-PCPG (mmol.l^-1)	0.97 (0.79-1.20)	0.800	1.10 (0.90-1.35)	0.342
Ln _LAP (cm.mmol.l^-1)	1.06 (0.89-1.26)	0.535	1.41 (1.02-1.96)	0.038

* For one SD increment in each continuous predictor, obtained from multivariate Cox proportional hazards regression model adjusted for age, smoking, systolic blood pressure, family history of premature CVD, diabetes, antihypertensive drug usage, HDL and non-HDL cholesterol, FPG, and 2h-PCPG , plus the TLGS intervention measures.
CVD, cardiovascular disease; FPG, fasting plasma glucose; HDL-C, high density lipoprotein cholesterol; HR, hazard ratio; LAP, lipid accumulation product; Ln, naturally logarithmically transformed; 2h-PCPG, 2-hour post-challenge plasma glucose;

ISSN: 1476-511X